Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2013 Oct;6(5):816-25.
doi: 10.1007/s12265-013-9507-7. Epub 2013 Aug 28.

Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up

Sander F Rodrigo  1 , Jan van Ramshorst, Georgette E Hoogslag, Helèn Boden, Matthijs A Velders, Suzanne C Cannegieter, Helene Roelofs, Imad Al Younis, Petra Dibbets-Schneider, Willem E Fibbe, Jaap Jan Zwaginga, Jeroen J Bax, Martin J Schalij, Saskia L Beeres, Douwe E Atsma
Affiliations
Controlled Clinical Trial

Intramyocardial injection of autologous bone marrow-derived ex vivo expanded mesenchymal stem cells in acute myocardial infarction patients is feasible and safe up to 5 years of follow-up

Sander F Rodrigo et al. J Cardiovasc Transl Res. 2013 Oct.

Abstract

In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates the safety and feasibility of intramyocardial MSC injection in nine patients, shortly after AMI during short-term and 5-year follow-up. Periprocedural safety analysis demonstrated one transient ischemic attack. No other adverse events related to MSC treatment were observed during 5-year follow-up. Clinical events were compared to a nonrandomized control group comprising 45 matched controls. A 5-year event-free survival after MSC-treatment was comparable to controls (89 vs. 91 %, P = 0.87). Echocardiographic imaging for evaluation of left ventricular function demonstrated improvements up to 5 years after MSC treatment. These findings were not significantly different when compared to controls. The present safety and feasibility study suggest that intramyocardial injection of MSC in patients shortly after AMI is feasible and safe up to 5-year follow-up.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart of patients included for MSC injection. PCI percutaneous coronary intervention, SPECT single-photon emission computed tomography
Fig. 2
Fig. 2
Kaplan–Meier curve for event-free survival of death, MI, revascularization and admission for heart failure. Event-free survival at 5 years follow-up was comparable between MSC-treated patients and controls (P = 0.97)
Fig. 3
Fig. 3
Individual improvements in segmental perfusion during exercise and rest after 3 months follow-up. Patients treated with MSCs showed a significant improvement in summed stress score (P < 0.01) and summed rest score (P = 0.04) when compared to baseline
Fig. 4
Fig. 4
LV ejection fraction during follow-up for MSC-treated patients and controls. MSC-treated patients demonstrated a significant improvement in LV ejection fraction during 12 months follow-up (from 48 ± 2 to 57 ± 3 %) that was comparable to controls (45 ± 9 to 50 ± 12 %; ΔP = 0.28)
See this image and copyright information in PMC

References

    1. Jeevanantham V, Butler M, Saad A, Abdel-Latif A, Zuba-Surma EK, Dawn B. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126:551–568. doi: 10.1161/CIRCULATIONAHA.111.086074. - DOI - PMC - PubMed
    1. Silva GV, Litovsky S, Assad JA, Sousa AL, Martin BJ, Vela D, Coulter SC, Lin J, Ober J, Vaughn WK, Branco RV, Oliveira EM, He R, Geng YJ, Willerson JT, Perin EC. Mesenchymal stem cells differentiate into an endothelial phenotype, enhance vascular density, and improve heart function in a canine chronic ischemia model. Circulation. 2005;111:150–156. doi: 10.1161/01.CIR.0000151812.86142.45. - DOI - PubMed
    1. Makino S, Fukuda K, Miyoshi S, Konishi F, Kodama H, Pan J, Sano M, Takahashi T, Hori S, Abe H, Hata J, Umezawa A, Ogawa S. Cardiomyocytes can be generated from marrow stromal cells in vitro. The Journal of Clinical Investigation. 1999;103:697–705. doi: 10.1172/JCI5298. - DOI - PMC - PubMed
    1. Dai W, Hale SL, Martin BJ, Kuang JQ, Dow JS, Wold LE, Kloner RA. Allogeneic mesenchymal stem cell transplantation in postinfarcted rat myocardium: short- and long-term effects. Circulation. 2005;112:214–223. doi: 10.1161/CIRCULATIONAHA.104.527937. - DOI - PubMed
    1. Chen SL, Fang WW, Ye F, Liu YH, Qian J, Shan SJ, Zhang JJ, Chunhua RZ, Liao LM, Lin S, Sun JP. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American Journal of Cardiology. 2004;94:92–95. doi: 10.1016/j.amjcard.2004.03.034. - DOI - PubMed

Publication types

MeSH terms

Associated data

LinkOut - more resources